Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.

Here, we describe the development of a series of highly selective PAR4 antagonists with nanomolar potency and selectivity versus PAR1, derived from the indole-based 3. Of these, 9j (PAR4 IC50 = 445 nM, PAR1 response IC50 > 30 μM) and 10h (PAR4 IC50 = 179 nM, PAR1 response IC50 > 30 μM) maintained an overall favorable in vitro DMPK profile, encouraging rat/mouse in vivo pharmacokinetics (PK) and activity against γ-thrombin.

[1]  Melody Bomgardner,et al.  Start-ups with robots seek to scale up synthetic biology , 2016 .

[2]  T. Lindahl,et al.  Protease‐activated receptor 4 is more important than protease‐activated receptor 1 for the thrombin‐induced procoagulant effect on platelets , 2016, Journal of thrombosis and haemostasis : JTH.

[3]  Julie L. Engers,et al.  Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. , 2014, Bioorganic & medicinal chemistry letters.

[4]  H. Hamm,et al.  Synthesis of Indole Derived Protease-Activated Receptor 4 Antagonists and Characterization in Human Platelets , 2013, PloS one.

[5]  H. Hamm,et al.  Protease-Activated Receptor (PAR) 1 and PAR4 Differentially Regulate Factor V Expression from Human Platelets , 2013, Molecular Pharmacology.

[6]  Marc P. Bonaca,et al.  Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial , 2012, The Lancet.

[7]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[8]  C. Held,et al.  The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. , 2009, American heart journal.

[9]  M. Brookhart,et al.  Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. , 2008, The American journal of cardiology.

[10]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[11]  D. Ramsdale,et al.  ABC of interventional cardiology: Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction , 2003 .

[12]  Chin‐Chung Wu,et al.  Synthesis of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole analogues as novel antiplatelet agents. , 2001, Journal of medicinal chemistry.

[13]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[14]  T. Bowker,et al.  Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK) , 2000, European heart journal.

[15]  S. Coughlin,et al.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. , 1999, The Journal of clinical investigation.

[16]  C. Patrono,et al.  Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? , 1998, Thrombosis research.

[17]  Scott R. Presnell,et al.  Cloning and characterization of human protease-activated receptor 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[19]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.